febuxostat has been researched along with Disease Models, Animal in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.67) | 29.6817 |
| 2010's | 15 (50.00) | 24.3611 |
| 2020's | 13 (43.33) | 2.80 |
| Authors | Studies |
|---|---|
| B-Rao, C; Bahirat, U; Bajaj, K; Brahma, MK; Burudkar, S; Damre, A; Desai, A; Deshmukh, NJ; Dixit, A; Doshi, L; Ghosh, U; Keche, A; Khanna, S; Kulkarni-Almeida, A; Nemmani, KV; Shah, P; Sharma, R; Sivaramakrishnan, H; Srivastava, A; Tannu, P | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chiba, K; Iino, T; Kataoka, T; Odake, K; Sudo, A; Tsujii, M | 1 |
| Aizawa, T; Chen, W; Fujita, R; Hagiwara, Y; Kanzaki, M; Li, Y; Ogawa, K; Suzuki, K; Takahashi, T; Tsuchiya, M; Yabe, Y; Yoshida, S | 1 |
| Cai, Y; Cai, Z; Chen, T; Huang, X; Mi, X; Shui, G; Wang, F | 1 |
| Han, H; Li, X; Tian, J; Yan, Z; Ye, F; Zhang, X | 1 |
| Chen, G; Honda, M; Kaneko, S; Matsui, C; Mizukoshi, E; Nagashimada, M; Nagata, N; Ni, Y; Nishikawa, T; Ota, T; Sakai, Y; Shimakami, T; Shirakura, T; Xu, L; Yamashita, T; Zhuge, F | 1 |
| Anzai, T; Fukushima, A; Furihata, T; Higashikawa, K; Kakutani, N; Katayama, T; Kinugawa, S; Kuge, Y; Maekawa, S; Matsumoto, J; Nakajima, T; Nakano, I; Nambu, H; Nio-Kobayashi, J; Obata, Y; Sabe, H; Saito, A; Shirakawa, R; Takada, S; Tsuda, M; Yamanashi, K; Yasui, H; Yokota, T | 1 |
| Hayama, Y; Kuribayashi-Okuma, E; Morimoto, C; Omizo, H; Shibata, S; Tamura, Y; Uchida, S; Ueno, M | 1 |
| Bachman, TN; Baust, JJ; Du, J; Ghosh, S; Hahn, SA; Kelley, EE; Lebensburger, JD; Lewis, SE; McMahon, B; Ofori-Acquah, SF; Oh, JY; Patel, RP; Schmidt, HM; Straub, AC; Vitturi, DA; Wang, Y; Williams, XM; Wood, KC; Yuan, S | 1 |
| Huang, X; Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Yi, HK; Zhang, JW | 1 |
| Adachi, T; Kanamura, N; Kobara, M; Nakata, T; Nessa, N; Pezzotti, G; Toba, H; Yamamoto, T | 1 |
| Morcos, GNB; Nadwa, EH; Salama, NM; Shafik, AN | 1 |
| Andrei, C; Chirita, C; Ciotu, CI; Fischer, MJM; Mihai, DP; Negres, S; Nitulescu, GM; Olaru, OT; Seremet, OC; Ungurianu, A; Zanfirescu, A; Zbarcea, CE | 1 |
| Aonuma, K; Duo, F; Ieda, M; Li, S; Mori, H; Murakata, Y; Murakoshi, N; Nogami, A; Okabe, Y; Sato, A; Shimoda, Y; Song, Z; Tajiri, K; Xu, D; Yuan, Z | 1 |
| Damarla, M; Damico, RL; Gao, L; Hassoun, PM; Johnston, LF; Kim, BS; Kolb, TM; Liu, G; Varela, L; Wang, L | 1 |
| Ako, J; Fukaya, H; Igarashi, T; Kishihara, J; Murakami, M; Nakamura, H; Niwano, H; Niwano, S; Oikawa, J; Satoh, A; Tamaki, H; Yoshizawa, T | 1 |
| Ito, O; Kohzuki, M; Kurosawa, R; Miura, T; Nakamura, T; Namai-Takahashi, A; Sakuyama, A; Takahashi, J | 1 |
| Chuma, M; Fujino, H; Fukushima, K; Goda, M; Horinouchi, Y; Ikeda, Y; Ikuto, R; Imanishi, M; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, M; Murai, Y; Takechi, K; Tsuchiya, K; Zamami, Y | 1 |
| Amaral, JH; Castro, MM; Conde-Tella, SO; Gerlach, RF; Guimarães, DA; Pinheiro, LC; Rizzi, E; Tanus-Santos, JE | 1 |
| Hisaka, A; Kurebayashi, N; Miyano, K; Nonaka, M; Sakurai, T; Sato, H; Uezono, Y; Uzu, M; Yanagihara, K | 1 |
| Busso, N; Ives, A; Kobayashi, T; Matsui, C; Nomura, J; Shirakura, T; So, A; Tamura, M; Tsujimoto, S; Yamanaka, Y | 1 |
| Kobayashi, T; Masuzaki, H; Matsui, C; Nomura, J; Shirakura, T; Tamura, M | 1 |
| Fahmi, AN; Salem, HA; Shebl, AM; Shehatou, GS | 1 |
| Komers, R; Oyama, TT; Schneider, J; Xu, B | 1 |
| Chung, BH; Jin, J; Jin, L; Kim, HS; Lim, SW; Yang, CW | 1 |
| Bache, RJ; Chen, Y; Hu, X; Lu, Z; Wessale, JL; Xu, X; Zhang, P; Zhao, L | 1 |
| Inoue, K; Isaka, Y; Kaimori, J; Kawada, N; Matsui, I; Moriyama, T; Omori, H; Rakugi, H; Takabatake, Y; Ueda, Y; Yamamoto, R | 1 |
| Alonso-Pacho, A; de la Puerta González-Quevedo, C; Fabregate-Fuente, M; Sabán-Ruiz, J | 1 |
| Avila-Casado, C; Franco, M; Johnson, RJ; Sánchez-Lozada, LG; Soto, V; Tapia, E; Wessale, JL; Zhao, L | 1 |
1 review(s) available for febuxostat and Disease Models, Animal
| Article | Year |
|---|---|
Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Febuxostat; Heart Failure; Humans; Inflammation; Ischemia; Rabbits; Rats; Renal Insufficiency, Chronic; Thiazoles; Treatment Outcome; Xanthine Oxidase | 2013 |
1 trial(s) available for febuxostat and Disease Models, Animal
| Article | Year |
|---|---|
Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.
Topics: Actins; Animals; Cadherins; Caspases; Disease Models, Animal; Epithelial-Mesenchymal Transition; Febuxostat; Fibronectins; Hyperuricemia; Inflammasomes; Interleukin-18; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Renal Insufficiency, Chronic; Uric Acid; Vimentin | 2022 |
28 other study(ies) available for febuxostat and Disease Models, Animal
| Article | Year |
|---|---|
Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.
Topics: Administration, Oral; Animals; Cytosine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Hyperuricemia; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Rats, Wistar; Structure-Activity Relationship; Time Factors; Xanthine Oxidase | 2012 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Febuxostat treatment attenuates oxidative stress and inflammation due to ischemia-reperfusion injury through the necrotic pathway in skin flap of animal model.
Topics: Animals; Disease Models, Animal; Febuxostat; Inflammation; Necrosis; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2021 |
Tissue accumulation of neutrophil extracellular traps mediates muscle hyperalgesia in a mouse model.
Topics: Animals; Disease Models, Animal; DNA; Extracellular Traps; Febuxostat; Histones; Hyperalgesia; Mice; Muscles; Neutrophils; Uric Acid | 2022 |
Urate Transporter URAT1 in Hyperuricemia: New Insights from Hyperuricemic Models.
Topics: Animals; Benzbromarone; Disease Models, Animal; Febuxostat; HEK293 Cells; Humans; Hyperuricemia; Kidney; Male; Mice, Inbred ICR; Organic Anion Transporters; Organic Cation Transport Proteins; Uric Acid | 2019 |
Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Topics: Allopurinol; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Febuxostat; Hyperuricemia; Insulin Resistance; Lipid Peroxidation; Liver; Macrophage Activation; Mice, Inbred C57BL; Molecular Targeted Therapy; Uric Acid; Xanthine Oxidase | 2020 |
Inhibition of xanthine oxidase in the acute phase of myocardial infarction prevents skeletal muscle abnormalities and exercise intolerance.
Topics: Animals; Cell Hypoxia; Cell Line; Disease Models, Animal; Enzyme Inhibitors; Exercise Tolerance; Febuxostat; Male; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle Strength; Muscle, Skeletal; Muscular Atrophy; Myocardial Infarction; Reactive Oxygen Species; Ribosomal Protein S6 Kinases, 70-kDa; Time Factors; TOR Serine-Threonine Kinases; Xanthine Oxidase | 2021 |
Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Febuxostat; Heart; Hyperuricemia; Kidney Diseases; Kidney Function Tests; Male; Myocardium; Nephrectomy; Oxidative Stress; Oxonic Acid; Protective Agents; Rats, Sprague-Dawley; Xanthine Oxidase | 2020 |
Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Animals; Disease Models, Animal; Enzyme Inhibitors; Erythrocytes; Febuxostat; Hemodynamics; Hemolysis; Liver; Male; Mice, Inbred C57BL; Mice, Knockout; Pulmonary Artery; Ventricular Function; Xanthine Oxidase | 2021 |
Inosine induces acute hyperuricaemia in rhesus monkey (
Topics: Acute Disease; Allopurinol; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Febuxostat; Hyperuricemia; Imino Furanoses; Inosine; Macaca mulatta; Male; Pyrimidinones; Reproducibility of Results; Uric Acid | 2021 |
Febuxostat Attenuates the Progression of Periodontitis in Rats.
Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Antioxidants; Blood Glucose; Blood Pressure; Body Weight; Disease Models, Animal; Febuxostat; Gingiva; Insulin Resistance; Interleukin-1beta; Ligation; Male; Osteoclasts; Osteoprotegerin; Oxidative Stress; Periodontitis; Rats, Wistar; Tumor Necrosis Factor-alpha; X-Ray Microtomography; Xanthine Dehydrogenase | 2021 |
Comparing the Effects of Febuxostat and Allopurinol in an Animal Model of Metabolic Syndrome.
Topics: Allopurinol; Animals; Blood Glucose; Blood Pressure; Body Weight; Catalase; Disease Models, Animal; Febuxostat; Glutathione Peroxidase; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Xanthine Oxidase | 2021 |
Effects of Venlafaxine, Risperidone and Febuxostat on Cuprizone-Induced Demyelination, Behavioral Deficits and Oxidative Stress.
Topics: Animals; Corpus Callosum; Cuprizone; Disease Models, Animal; Drug Evaluation, Preclinical; Febuxostat; Female; HEK293 Cells; Humans; Mice, Inbred C57BL; Motor Activity; Multiple Sclerosis; Neurotransmitter Agents; Risperidone; TRPA1 Cation Channel; Venlafaxine Hydrochloride | 2021 |
Xanthine oxidase inhibitor febuxostat reduces atrial fibrillation susceptibility by inhibition of oxidized CaMKII in Dahl salt-sensitive rats.
Topics: Allopurinol; Animals; Atrial Fibrillation; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Connexins; Disease Models, Animal; Enzyme Inhibitors; Febuxostat; Fibrosis; Gap Junction alpha-5 Protein; Gap Junctions; Hypertension; Male; Myocytes, Cardiac; Oxidation-Reduction; Phosphorylation; Rats, Inbred Dahl; Ryanodine Receptor Calcium Release Channel; Sodium Chloride, Dietary; Xanthine Oxidase | 2021 |
XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Febuxostat; Lipopolysaccharides; Lung Injury; Male; Mice, Inbred C57BL; Sepsis; Survival Analysis; Xanthine Dehydrogenase | 2017 |
Antiremodeling Effect of Xanthine Oxidase Inhibition in a Canine Model of Atrial Fibrillation.
Topics: Animals; Antioxidants; Atrial Fibrillation; Atrial Remodeling; Disease Models, Animal; Dogs; Echocardiography; Febuxostat; Female; Fibronectins; Fibrosis; Gout Suppressants; Heart Atria; Hemodynamics; Oxidative Stress; Reactive Oxygen Species; Xanthine Oxidase | 2018 |
Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake-Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats.
Topics: Animals; Collagen; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Febuxostat; Fibrosis; Heart Ventricles; Hypertrophy, Left Ventricular; Male; NADPH Oxidases; Phosphorylation; Rats, Inbred Dahl; Reactive Oxygen Species; Renin-Angiotensin System; Sodium Chloride, Dietary; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2019 |
Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis.
Topics: Actins; Adventitia; Angiotensin II; Animals; Aorta; Aortic Diseases; Disease Models, Animal; Febuxostat; Fibroblasts; Fibrosis; Gout Suppressants; Hypertension; Macrophages; Male; Mice, Inbred C57BL; Transforming Growth Factor beta1; Vascular Remodeling; Xanthine Oxidase | 2019 |
Nitrite treatment downregulates vascular MMP-2 activity and inhibits vascular remodeling in hypertension independently of its antihypertensive effects.
Topics: Animals; Antihypertensive Agents; Antioxidants; Aorta; Blood Pressure; Disease Models, Animal; Febuxostat; Gene Expression Regulation; Humans; Hypertension, Renovascular; Matrix Metalloproteinase 2; Muscle, Smooth, Vascular; Nitric Oxide; Nitrites; Oxidative Stress; Rats; Reactive Oxygen Species; Vascular Remodeling; Xanthine Oxidase | 2019 |
A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain.
Topics: Administration, Oral; Animals; Brain; Cachexia; Disease Models, Animal; Febuxostat; Male; Mice, Inbred BALB C; Neoplasms; Purines; Xanthine Oxidase | 2019 |
Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Cholesterol; Cytokines; Disease Models, Animal; Endothelial Cells; Febuxostat; Gout Suppressants; Inflammation; L-Lactate Dehydrogenase; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Plaque, Atherosclerotic; Reactive Oxygen Species; Thiazoles; Xanthine Oxidase | 2014 |
Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Febuxostat; Hypertension; Male; Oxidative Stress; Rats, Inbred SHR; Rats, Inbred WKY; Time Factors; Tyrosine; Vasodilation; Vasodilator Agents; Xanthine Oxidase | 2016 |
Febuxostat exerts dose-dependent renoprotection in rats with cisplatin-induced acute renal injury.
Topics: Acute Kidney Injury; Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cisplatin; Creatinine; Cytoprotection; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Febuxostat; Glutathione; Inflammation Mediators; Kidney; L-Lactate Dehydrogenase; Male; Malondialdehyde; Nitric Oxide; Oxidative Stress; Proteinuria; Rats, Sprague-Dawley; Serum Albumin; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Urological Agents; Xanthine Oxidase | 2016 |
Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Enzyme Inhibitors; Febuxostat; Male; Oxidative Stress; Rats; Rats, Zucker; Xanthine Oxidase | 2016 |
The Protective Effect of Febuxostat on Chronic Tacrolimus-Induced Nephrotoxicity in Rats.
Topics: Animals; Anion Transport Proteins; Apoptosis; Calcineurin Inhibitors; Disease Models, Animal; Febuxostat; Gout Suppressants; Humans; Hyperuricemia; Kidney; Kidney Transplantation; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tacrolimus | 2017 |
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice.
Topics: Animals; Disease Models, Animal; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Systole; Thiazoles; Ventricular Dysfunction, Left | 2008 |
Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.
Topics: Animals; Cell Movement; Cytokines; Disease Models, Animal; Febuxostat; Fibrosis; Kidney; Kidney Diseases; Macrophages; Male; Nephritis, Interstitial; Oxidative Stress; Rats; Rats, Sprague-Dawley; Thiazoles; Transforming Growth Factor beta; Ureteral Obstruction; Xanthine Oxidase | 2012 |
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Topics: Animals; Disease Models, Animal; Febuxostat; Hyperuricemia; Kidney; Kidney Failure, Chronic; Male; Microcirculation; Nephrectomy; Oxonic Acid; Rats; Rats, Wistar; Recovery of Function; Thiazoles; Treatment Outcome | 2008 |